UCL Cancer Institute


Current Trials



 

How to Refer a Patient for Phase I Assessment

Email:  phase1cancer@uclh.nhs.uk   Telephone: +44 (0)20 3447 6036

Post:  Marivic Ricamara, Sr. Research Nurse, Clinical Research Facility, EGA Wing, UCH,
235 Euston Road London NW1 2BU

 



EudraCT #
Study full title
Principal Investigator
Generic
2009-017817-31 Phase I Open-label, Dose Escalation Study of S-222611 in Patients with Solid Tumours Dr. Martin Foster
2010-024237-23 An open-Label Phase I/IIa Study of Intravenous BAL101553 in Adult Patients with Advanced Solid Tumors Dr. Rebecca Kristeleit
2011-004250-26 A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients with gBRCA Mutation Breast Cancer or Other Solid Tumor Dr. Rebecca Kristeleit
2012-001184-69 An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients with Solid Tumors Dr. Rebecca Kristeleit
2010-022442-25 A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects with Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma Prof. Tim Meyer
Breast
2010-024454-10 An open label, phase II trial of afatinib with or without vinorelbine for the treatment of HER2-overexpressing Inflammatory Breast Cancer Prof. Charles Swanton
2006-002348-27 A phase II Proof of Principle Trial of the activity of the PARP-1 inhibitor, AG-014699, in known carriers of a BRCA1 or BRCA2 mutation with locally advanced or metastatic breast or advanced ovarian cancer Dr. Alison Jones
Gastro-Intestinal
2011-005547-27 A Phase II, multicenter, open-label, randomized study evaluating the efficacy and safety of FOLFIRI+MEHD7945A VERSUS FOLFIRI+CETUXIMAB in second line in patients with KRAS WILD-TYPE metastatic colorectal cancer Dr. John Bridgewater
2012-000317-36 A Phase IIA Open Label, Adaptive, Randomized Clinical Trial of Dalotuzumab (MK-0646) Treatment in Combination with Irinotecan versus Cetuximab and Irinotecan for Patients with Metastatic Rectal Cancers (mRC) Expressing High IGF-1/Low IGF-2 Levels Prof. Daniel Hochhauser
2010-019602-16 Lapatinib in Early Oesophago-Gastric Cancer An Open label phase Ib study of lapatinib in combination with oxaliplatin and capecitabine in early HER-2 over-expressing oesophago-gastric cancer Assess ability of ex vivo molecular response to predict molecular response Prof. Daniel Hochhauser
2009-011992-61 Phase II randomized trial of MEK inhibitor MSC1936369B or placebo combined with gemcitabine in metastatic pancreas cancer subjects Dr. John Bridgewater
Endometrial
2011-000266-35 A phase II, open-label, non-randomized, multi-center study to evaluate the efficacy of oral TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced endometrial cancer Dr. Rebecca Kristeleit
2011-003062-32 A randomized phase II non-comparative study of the efficacy of PF-04691502 and PF-05212384 in patients with recurrent endometrial cancer Dr. Rebecca Kristeleit
Gynea
2012-001472-10 A randomized, open-label, Phase 2 study of the IDO inhibitor INCB024360 versus tamoxifen for subjects with biochemical-recurrent-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer following complete remission with first-line chemotherapy Dr. Rebecca Kristeleit
2006-002348-27 A phase II Proof of Principle Trial of the activity of the PARP-1 inhibitor, AG-014699, in known carriers of a BRCA1 or BRCA2 mutation with locally advanced or metastatic breast or advanced ovarian cancer Dr. Alison Jones
Haematology
2010-022445-20 A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma Dr. Neil Rabin
2010-023772-71 An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of MLN9708, a Next-Generation Proteasome Inhibitor, Administered in Combination With a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment Prof. Kwee Yong
2011-001914-33 A Phase I/IIa, Dose-Escalation, Study of CHR-3996 in Combination with Tosedostat in Participants with Relapsed, Refractory Multiple Myeloma Prof. Kwee Yong
2012-000842-36 A Phase I/IIa trial of VTD-panobinostat treatment and panobinostat maintenance in relapsed and relapsed/refractory multiple myeloma patients Prof. Kwee Yong
2010-022442-25 A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects with Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma Prof. Tim Meyer
Hepatobiliary
2009-011924-14 A multicentre, open label, phase I / Randomized, Double-Blind, Placebo-controlled Phase 2 study to evaluate safety, pharmacokinetics and efficacy of BIBF 1120 in comparison with Sorafenib for advanced hepatocellular carcinoma patients Prof. Tim Meyer
2011-000752-41 An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination with Sorafenib versus Sorafenib Alone as First Line Therapy in Patients with Hepatocellular Carcinoma Prof. Tim Meyer
Lung
2010-022950-17 A Phase 1/2 Study to Assess the Safety and Efficacy of Lorvotuzumab Mertansine (IMGN901) in Combination with Carboplatin/Etoposide in Patients with Advanced Solid Tumors including Extensive Stage Small Cell Lung Cancer Dr. Martin Foster
2012-000966-40 Trial to Assess the benefit of folate-Receptor tarGEteted Treatment of second-line NSCLC.
A Randomized, Open-Label Phase 2 Study of EC145 Single-agent and the Combination of EC145 plus Docetaxel Versus Docetaxel Alone in Participants with Folate-Receptor Positive [FR(++)] Second Line NSCLC
Dr. Martin Foster
2012-003174-83 A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination with Carboplatin and Etoposide Followed by LY2940680 versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients with Extensive-Stage Small Cell Lung Cancer Dr. Martin Foster
 
 
Page last Modified: 23 June 2013